US HHS misses implementation deadline for transparency provision; drug, device firms concerned
This article was originally published in Clinica
Executive Summary
A failure by the US Department of Health and Human Services to implement by its 1 October deadline procedures to explain what healthcare product firms will have to do to meet a forthcoming transparency provision has drawn concern from pharma and medtech companies.